西格列汀辅助治疗阻塞性睡眠呼吸暂停综合征合并肥胖T2DM的效果OA
Effects of Sitagliptin as an Adjuvant Therapy for Obstructive Sleep Apnea-hypopnea Syndrome Complicated with Obesity and Type 2 Diabetes Mellitus
目的:探讨分析西格列汀辅助治疗阻塞性睡眠呼吸暂停综合征(OSAHS)合并肥胖2型糖尿病(T2DM)患者的效果.方法:选取2023年1月1日至2025年1月31日扬州大学附属淮安医院收治的阻塞性睡眠呼吸暂停综合征合并肥胖2型糖尿病患者120例作为研究对象,按照随机信封抽签原则分为观察组与对照组,每组60例.对照组给予常规治疗,观察组在对照组治疗的基础上给予西格列汀治疗,2组治疗观察时间都为12周,记录患者的预后情况.结果:2组治疗后的呼吸暂停低通气指数(AHI)低于治疗前,且观察组治疗后AHI低于对照组,差异有统计学意义(P＜0.05);2组治疗后的空腹血糖(FBG)、餐后2 h血糖(PBG)低于治疗前,且观察组治疗后的空腹血糖、餐后2 h血糖显著低于对照组,差异有统计学意义(P＜0.05);2组治疗后的体质量指数(BMI)低于治疗前,且观察组治疗后的BMI显著低于对照组,差异有统计学意义(P＜0.05);观察组治疗期间的低血糖、胃肠道不适、头痛、呼吸道感染等不良反应发生率与对照组比较,差异无统计学意义(P＞0.05).结论:西格列汀辅助治疗阻塞性睡眠呼吸暂停综合征合并肥胖2型糖尿病患者能减少呼吸暂停低通气指数,降低患者的空腹血糖、餐后2 h血糖,还可降低患者的体质量指数,且具有很好的安全性.
Objective:To explore and analyze the effects of sitagliptin as an adjuvant therapy in patients with obstructive sleep apnea-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus.Methods:A total of 120 patients with obstructive sleep apnea-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus admitted to Huai'an Hospital Affiliated to Yangzhou University from January 1,2023 to January 31,2025 were selected as the study subjects.They were divided into the ob-servation group and the control group according to the random envelope drawing method,with 60 cases in each group.The control group received conventional treatment,while the observation group received sitagliptin treatment on the basis of the treatment in the control group.Both groups were treated and observed for 12 weeks,and the prognosis of the patients was recorded.Results:Af-ter treatment,the apnea-hypopnea index(AHI)in both groups was lower than that before treatment,and the AHI in the observa-tion group was lower than that in the control group after treatment,with statistically significant differences(P＜0.05).After treat-ment,fasting blood glucose(FBG)and 2-hour postprandial blood glucose(2 h PBG)in both groups were lower than those before treatment,and FBG and 2 h PBG in the observation group were significantly lower than those in the control group after treatment,with statistically significant differences(P＜0.05).After treatment,the body mass index(BMI)in both groups was lower than that before treatment,and the BMI in the observation group was significantly lower than that in the control group after treatment,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions such as hypoglycemia,gastrointestinal discomfort,headache,and respiratory tract infection between the observation group and the control group during treatment(P＞0.05).Conclusion:Sitagliptin as an adjuvant therapy for patients with obstructive sleep apne-a-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus can reduce the apnea-hypopnea index,decrease fast-ing blood glucose and 2-hour postprandial blood glucose,and reduce body mass index,with good safety.
杨春晓;徐跃;齐书静
扬州大学附属淮安医院/淮安市第五人民医院内分泌科,淮安,223300扬州大学附属淮安医院/淮安市第五人民医院内分泌科,淮安,223300扬州大学附属淮安医院/淮安市第五人民医院内分泌科,淮安,223300
医药卫生
西格列汀阻塞性睡眠呼吸暂停综合征肥胖2型糖尿病呼吸暂停低通气指数安全性血糖
SitagliptinObstructive sleep apnea-hypopnea syndromeObesityType 2 diabetes mellitusApnea-hypopnea in-dexSafetyBlood glucose
《世界睡眠医学杂志》 2026 (2)
265-268,4
江苏省基础研究计划项目(BK2023065).
评论